Pyxis Oncology, Inc. is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. Pyxis develops its product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies.
Company profile
Ticker
PYXS
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Pyxis Securities Corporation ...
IRS number
831160910
PYXS stock data
Latest filings (excl ownership)
8-K
Pyxis Oncology Announces FDA Clearance of Two IND Applications
1 Dec 22
EFFECT
Notice of effectiveness
15 Nov 22
CORRESP
Correspondence with SEC
10 Nov 22
UPLOAD
Letter from SEC
3 Nov 22
S-3
Shelf registration
1 Nov 22
10-Q
2022 Q3
Quarterly report
1 Nov 22
8-K
Expands worldwide licensing agreement with Pfizer to obtain additional antibody-drug conjugate (ADC) platform components
1 Nov 22
8-K
Entry into a Material Definitive Agreement
7 Oct 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
8-K
Prioritized pipeline to focus on most advanced programs while maintaining financial flexibility to pursue business development opportunities
15 Aug 22
Latest ownership filings
4
Lara Sullivan
3 Jan 23
4
Jay Feingold
3 Jan 23
4
Connealy Pamela Yanchik
3 Jan 23
SC 13G
TANG CAPITAL PARTNERS LP
4 Nov 22
3
Initial statement of insider ownership
13 Oct 22
4
RACHEL HUMPHREY
15 Aug 22
3
RACHEL HUMPHREY
15 Aug 22
3
Jitendra Wadhane
9 Aug 22
SC 13D/A
Sullivan Lara
23 May 22
4
Change in insider ownership
27 Apr 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | |
|---|---|---|
| Revenue | ||
| Cost of revenue | ||
| Operating income | ||
| Operating margin | ||
| Net income | ||
| Net profit margin | ||
| Cash on hand | ||
| Change in cash | ||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 200.01 mm | 200.01 mm | 200.01 mm | 200.01 mm | 200.01 mm | |
| Cash burn (monthly) | 8.27 mm | (no burn) | 9.46 mm | 8.49 mm | 2.31 mm | |
| Cash used (since last report) | 34.57 mm | n/a | 39.55 mm | 35.50 mm | 9.64 mm | |
| Cash remaining | 165.44 mm | n/a | 160.46 mm | 164.51 mm | 190.37 mm | |
| Runway (months of cash) | 20.0 | n/a | 17.0 | 19.4 | 82.5 | |
Institutional ownership, Q3 2022
86.6% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 41 |
| Opened positions | 5 |
| Closed positions | 7 |
| Increased positions | 13 |
| Reduced positions | 8 |
| 13F shares | Current |
|---|---|
| Total value | 131.45 mm |
| Total shares | 30.41 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Lara Sullivan | 3.47 mm | $14.01 mm |
| Laurion Capital Management | 3.17 mm | $6.25 mm |
| PFE Pfizer | 2.99 mm | $32.82 mm |
| BVF | 2.94 mm | $5.79 mm |
| World Investments B.V. Bayer | 2.74 mm | $30.08 mm |
| Biotechnology Value Fund L P | 1.79 mm | $16.30 mm |
| Citadel Advisors | 1.53 mm | $3.02 mm |
| Perceptive Advisors | 1.53 mm | $3.01 mm |
| Tang Capital Management | 1.41 mm | $2.78 mm |
| BCS Barclays | 947.65 k | $1.87 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Jan 23 | Yanchik Connealy Pamela | Common Stock | Grant | Acquire A | No | No | 0 | 43,493 | 0.00 | 384,510 |
| 3 Jan 23 | Lara Sullivan | Common Stock | Grant | Acquire A | No | No | 0 | 95,684 | 0.00 | 1,452,320 |
| 3 Jan 23 | Jay Feingold | Common Stock | Grant | Acquire A | No | No | 0 | 53,931 | 0.00 | 520,542 |